Remke, Niklas
Bisht, Savita
Oberbeck, Sebastian
Nolting, Jens
Brossart, Peter
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung
Article History
Received: 17 July 2019
Accepted: 7 July 2020
First Online: 10 July 2020
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: Animal experiments described here comply with Directive 2010/63/EU and were approved by the government of the state of North Rhine-Westphalia. Mice were maintained according to the guidelines of the Federation of European Laboratory Animal Science Associations (FELASA). The studies were approved by the EC (131/11, 173/09).
: The strains <i>C57BL/6</i>-<i>Tg(TcraTcrb)1100Mjb/Crl</i> (OT I Mouse) and <i>C57BL/6</i>-<i>Tg(TcraTcrb)425Cbn/Crl</i> (OT II Mouse) were generously provided by J.G. van den Boorn (Dept. of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany). Each strain used in the study was originally supplied by Charles River.